PortfoliosLab logoPortfoliosLab logo
XDNA.TO vs. IBB
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

XDNA.TO vs. IBB - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in iShares Genomics Immunology and Healthcare Index ETF (XDNA.TO) and iShares Nasdaq Biotechnology ETF (IBB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

XDNA.TO is traded in CAD, while IBB is traded in USD. To make them comparable, the IBB values have been converted to CAD using the latest available exchange rates.

Returns By Period

In the year-to-date period, XDNA.TO achieves a 28.27% return, which is significantly higher than IBB's 15.20% return.


XDNA.TO

1D
-0.71%
1M
10.45%
6M
16.34%
YTD
28.27%
1Y
59.77%
3Y*
14.14%
5Y*
10Y*

IBB

1D
-0.31%
1M
10.91%
6M
12.43%
YTD
15.20%
1Y
48.22%
3Y*
16.21%
5Y*
5.91%
10Y*
8.74%
*Multi-year figures are annualized to reflect compound growth (CAGR)

XDNA.TO vs. IBB - Yearly Performance Comparison


2026 (YTD)2025202420232022
XDNA.TO
iShares Genomics Immunology and Healthcare Index ETF
28.27%12.10%5.54%-7.84%-14.85%
IBB
iShares Nasdaq Biotechnology ETF
15.20%22.14%5.85%1.29%15.99%

Correlation

The correlation between XDNA.TO and IBB is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.36

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (All Time)
Calculated using the full available price history since May 4, 2022

0.20

The correlation between XDNA.TO and IBB shifts across timeframes, from 0.20 (all time) to 0.36 (1 year), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

XDNA.TO vs. IBB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XDNA.TO
XDNA.TO Risk / Return Rank: 8989
Overall Rank
XDNA.TO Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
XDNA.TO Sortino Ratio Rank: 8787
Sortino Ratio Rank
XDNA.TO Omega Ratio Rank: 8383
Omega Ratio Rank
XDNA.TO Calmar Ratio Rank: 9696
Calmar Ratio Rank
XDNA.TO Martin Ratio Rank: 9090
Martin Ratio Rank

IBB
IBB Risk / Return Rank: 8585
Overall Rank
IBB Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
IBB Sortino Ratio Rank: 8585
Sortino Ratio Rank
IBB Omega Ratio Rank: 7878
Omega Ratio Rank
IBB Calmar Ratio Rank: 9191
Calmar Ratio Rank
IBB Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XDNA.TO vs. IBB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare Index ETF (XDNA.TO) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


XDNA.TOIBBDifference
Sharpe ratioReturn per unit of total volatility

+0.03

Sortino ratioReturn per unit of downside risk

-0.03

Omega ratioGain probability vs. loss probability

1.39

1.38

+0.01

Calmar ratioReturn relative to maximum drawdown

6.95

5.01

+1.95

Martin ratioReturn relative to average drawdown

15.82

12.93

+2.89

XDNA.TO vs. IBB - Sharpe Ratio Comparison

The current XDNA.TO Sharpe Ratio is 2.34, which is comparable to the IBB Sharpe Ratio of 2.31. The chart below compares the historical Sharpe Ratios of XDNA.TO and IBB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

XDNA.TO vs. IBB - Drawdown Comparison

The maximum XDNA.TO drawdown since its inception was -45.90%, which is greater than IBB's maximum drawdown of -39.09%. Use the drawdown chart below to compare losses from any high point for XDNA.TO and IBB.


Loading charts...

Drawdown Indicators


XDNA.TOIBBDifference

Max Drawdown

Largest peak-to-trough decline

-45.90%

-39.09%

-6.81%

Max Drawdown (1Y)

Largest decline over 1 year

-8.64%

-9.68%

+1.04%

Max Drawdown (3Y)

Largest decline over 3 years

-28.29%

-22.65%

-5.64%

Max Drawdown (5Y)

Largest decline over 5 years

-38.88%

Max Drawdown (10Y)

Largest decline over 10 years

-38.88%

Current Drawdown

Current decline from peak

-7.51%

-5.55%

-1.96%

Average Drawdown

Average peak-to-trough decline

-22.98%

-16.58%

-6.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.79%

3.74%

+0.05%

Volatility

XDNA.TO vs. IBB - Volatility Comparison

iShares Genomics Immunology and Healthcare Index ETF (XDNA.TO) has a higher volatility of 7.90% compared to iShares Nasdaq Biotechnology ETF (IBB) at 6.25%. This indicates that XDNA.TO's price experiences larger fluctuations and is considered to be riskier than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


XDNA.TOIBBDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.90%

6.25%

+1.65%

Volatility (6M)

Calculated over the trailing 6-month period

18.84%

16.41%

+2.43%

Volatility (1Y)

Calculated over the trailing 1-year period

25.66%

21.00%

+4.66%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.41%

22.93%

+2.48%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

25.41%

24.06%

+1.35%

XDNA.TO vs. IBB - Expense Ratio Comparison

XDNA.TO has a 0.44% expense ratio, which is lower than IBB's 0.47% expense ratio.


Dividends

XDNA.TO vs. IBB - Dividend Comparison

XDNA.TO's dividend yield for the trailing twelve months is around 0.25%, more than IBB's 0.22% yield.


PositionTTM20252024202320222021202020192018201720162015
IBB
iShares Nasdaq Biotechnology ETF
0.22%0.23%0.29%0.26%0.31%0.21%0.21%0.33%0.20%0.30%0.19%0.03%
XDNA.TO
iShares Genomics Immunology and Healthcare Index ETF
0.25%0.43%0.32%0.25%0.32%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions


XDNA.TO and IBB have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, XDNA.TO is cheaper at 0.44% per year. The better choice depends on whether you care most about return, fees, risk, or income.

XDNA.TO is cheaper with a 0.44% expense ratio, compared with 0.47% for IBB.

XDNA.TO tracks NYSE FactSet Global Genomics and Immuno Biopharma Index, while IBB tracks NASDAQ Biotechnology Index. Their fees differ too: 0.44% for XDNA.TO and 0.47% for IBB.

Portfolio Optimizer

Find the right allocation for XDNA.TO and IBB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer